SUN-334 Evaluation of the CCK-2 Receptor Agonist (177)Lu-PP-F11N for PRRT of Medullary Thyroid Carcinoma: Results of a Phase 0 "Lumed" Study

Introduction: Despite the introduction of new molecular targeted therapies, there is still an unmet need for an effective systemic therapy for advanced medullary thyroid carcinoma (MTC). As MTC expresses cholecystokinine-2 (CCK-2) receptors at a high incidence and density, targeting the CCK-2 recept...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:J Endocr Soc
Main Authors: Rottenburger, Christof, Nicolas, Guillaume, McDougall, Lisa, Kaul, Felix, Cachovan, Michal, Schibli, Roger, Geistlich, Susanne, Behe, Martin, Wild, Damian, Christ, Emanuel
Format: Artigo
Jezik:Inglês
Izdano: Endocrine Society 2019
Teme:
Tumor Biology
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6552824/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/js.2019-SUN-334
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki